Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs

Bibliography

• Thomas A, Rajan A, Lopez-Chavez A, et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013;24:577-85
   PubMed Web of Science ®Google Scholar
• Edwards SL, Beesley J, French JD, et al. Beyond gwass: Illuminating the dark road from association to function. Am J Hum Genet 2013;93:779-97
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Binkhorst L, Mathijssen RH, van Herk-Sukel MP, et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 2013;139:923-9
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Haraldsdottir S, Goldberg RM. How can next-generation sequencing (genomics) help us in treating colorectal cancer? Curr Colorectal Cancer Rep 2014;10:372-9
   PubMedGoogle Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 2015;64:S16-21
   PubMed Web of Science ®Google Scholar
• Nadauld L, Regan JF, Miotke L, et al. Quantitative and sensitive detection of cancer genome amplifications from formalin fixed paraffin embedded tumors with droplet digital PCR. Transl Med (Sunnyvale) 2012;2:1000107
   Google Scholar
• Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427-34
   PubMed Web of Science ®Google Scholar
• International HapMap C. A haplotype map of the human genome. Nature 2005;437:1299-320
   PubMed Web of Science ®Google Scholar
• Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line folfox-4 chemotherapy. J Clin Oncol 2007;25:1247-54
   PubMed Web of Science ®Google Scholar
• Pander J, Wessels JA, Gelderblom H, et al. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 2011;22:1147-53
   PubMed Web of Science ®Google Scholar
• Erculj N, Kovac V, Hmeljak J, et al. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy. J Thorac Oncol 2012;7:1609-17
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Yang D, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS ONE 2013;8:e66774
   PubMed Web of Science ®Google Scholar
• Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009;27:5519-28
   PubMed Web of Science ®Google Scholar
• Emmert-Streib F, Tripathi S, de Matos Simoes R. Harnessing the complexity of gene expression data from cancer: from single gene to structural pathway methods. Biol Direct 2012;7:44
   PubMedGoogle Scholar
• Macgregor PF, Squire JA. Application of microarrays to the analysis of gene expression in cancer. Clin Chem 2002;48:1170-7
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70
   PubMed Web of Science ®Google Scholar
• Cheung VG, Morley M, Aguilar F, et al. Making and reading microarrays. Nat Genet 1999;21:15-19
   PubMed Web of Science ®Google Scholar
• Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-85
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Ezura Y, Ishida R, et al. Accuracy of genotyping for single nucleotide polymorphisms by a microarray-based single nucleotide polymorphism typing method involving hybridization of short allele-specific oligonucleotides. DNA Res 2002;9:59-62
   PubMed Web of Science ®Google Scholar
• Landi S, Gemignani F, Gioia-Patricola L, et al. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 2003;35:816-20. 22, 24-7
   PubMed Web of Science ®Google Scholar
• Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998;280:1077-82
   PubMed Web of Science ®Google Scholar
• Mao X, Young BD, Lu YJ. The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics 2007;8:219-28
   PubMed Web of Science ®Google Scholar
• Kim IJ, Lim SB, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007;50:1342-53
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008;5:577-87
   PubMedGoogle Scholar
• Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002;4:R3
   PubMed Web of Science ®Google Scholar
• Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93
   PubMed Web of Science ®Google Scholar
• Naoi Y, Kishi K, Tanei T, et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011;117:3682-90
   PubMed Web of Science ®Google Scholar
• Friedman DR, Weinberg JB, Barry WT, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res 2009;15:6947-55
   PubMed Web of Science ®Google Scholar
• Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007;25:773-80
   PubMed Web of Science ®Google Scholar
• Folgueira MA, Carraro DM, Brentani H, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-43
   PubMed Web of Science ®Google Scholar
• Low SK, Takahashi A, Mushiroda T, et al. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res 2014;20:2541-52
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Tsunoda T, et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in japanese. Hum Mol Genet 2012;21:1665-72
   PubMed Web of Science ®Google Scholar
• Innocenti F, Owzar K, Cox NL, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2012;18:577-84
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27:5972-8
   PubMed Web of Science ®Google Scholar
• Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010;28:4674-82
   PubMed Web of Science ®Google Scholar
• Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-109
   PubMed Web of Science ®Google Scholar
• Wu X, Ye Y, Rosell R, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011;103:817-25
   PubMed Web of Science ®Google Scholar
• Sato Y, Yamamoto N, Kunitoh H, et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011;6:132-8
   PubMed Web of Science ®Google Scholar
• Hu L, Wu C, Zhao X, et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012;18:5507-14
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sai K, Saito Y, et al. Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect. PLoS One 2014;9:e105160
   PubMedGoogle Scholar
• Low SK, Chung S, Takahashi A, et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in biobank Japan. Cancer Sci 2013;104:1074-82
   PubMed Web of Science ®Google Scholar
• Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol 2013;76:370-80
   PubMed Web of Science ®Google Scholar
• Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299:1335-44
   PubMed Web of Science ®Google Scholar
• Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11:241-6
   PubMed Web of Science ®Google Scholar
• Xuan J, Yu Y, Qing T, et al. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013;340:284-95
   PubMed Web of Science ®Google Scholar
• Pareek CS, Smoczynski R, Tretyn A. Sequencing technologies and genome sequencing. J Appl Genet 2011;52:413-35
   PubMed Web of Science ®Google Scholar
• Ku CS, Naidoo N, Wu M, et al. Studying the epigenome using next generation sequencing. J Med Genet 2011;48:721-30
   PubMed Web of Science ®Google Scholar
• Zhang J, Chiodini R, Badr A, et al. The impact of next-generation sequencing on genomics. J Genet Genom 2011;38:95-109
   PubMed Web of Science ®Google Scholar
• MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013;31:1815-24
   PubMed Web of Science ®Google Scholar
• Royer-Bertrand B, Rivolta C. Whole genome sequencing as a means to assess pathogenic mutations in medical genetics and cancer. Cell Mol Life Sci 2014;72(8):1463-71
   PubMed Web of Science ®Google Scholar
• Busby MA, Stewart C, Miller CA, et al. Scotty: a web tool for designing rna-seq experiments to measure differential gene expression. Bioinformatics 2013;29:656-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Zheng Y, Hou L. Pharmacogenomic discovery delineating the genetic basis of drug response. Curr Genet Med Rep 2013;1:143-9
   Google Scholar
• Tennessen JA, Bigham AW, O’Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012;337:64-9
   PubMed Web of Science ®Google Scholar
• Genomes Project C, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65
   PubMed Web of Science ®Google Scholar
• Pasaniuc B, Rohland N, McLaren PJ, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet 2012;44:631-5
   PubMed Web of Science ®Google Scholar
• Pant S, Weiner R, Marton MJ. Navigating the rapids: The development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol 2014;4:78
   PubMedGoogle Scholar
• Nagarajan N, Pop M. Sequencing and genome assembly using next-generation technologies. Meth Mol Biol 2010;673:1-17
   PubMedGoogle Scholar
• Zhang L, Chen L, Sah S, et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist 2014;19:336-43
   PubMed Web of Science ®Google Scholar
• Choudhary A, Mambo E, Sanford T, et al. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med Genom 2014;7:62
   PubMed Web of Science ®Google Scholar
• Ingle JN. Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet 2013;58:306-12
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Rand JV, et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J Clin Pathol 2014;67:968-73
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Normanno N, Maiello E, et al. Clinical activity of folfiri plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the capri-goim trial. Ann Oncol 2014;25:1756-61
   PubMed Web of Science ®Google Scholar
• Zardavas D, Maetens M, Irrthum A, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer 2014;111:1881-7
   PubMed Web of Science ®Google Scholar
• Saal LH, Vallon-Christersson J, Hakkinen J, et al. The sweden cancerome analysis network - breast (SCAN-B) initiative: A large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med 2015;7:20
   PubMedGoogle Scholar
• Tian C, Gregersen PK, Seldin MF. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008;17:R143-50
   PubMed Web of Science ®Google Scholar
• Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Bocci G, Polillo M, et al. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 2011;12:932-43
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Polillo M, Capecchi M, et al. The c.480c>g polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenom J 2014;14:328-35
   PubMed Web of Science ®Google Scholar
• Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-96
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Hosono N, et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 2010;20:565-8
   PubMed Web of Science ®Google Scholar
• Theile D, Grebhardt S, Haefeli WE, et al. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009;78:1366-73
   PubMed Web of Science ®Google Scholar
• Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010;42:570-5
   PubMed Web of Science ®Google Scholar
• Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000;410:107-20
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov A, Anderson TJ, et al. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenom J 2012;12:10-21
   PubMed Web of Science ®Google Scholar
• Modlich O, Prisack HB, Munnes M, et al. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004;10:6418-31
   PubMed Web of Science ®Google Scholar
• Glaysher S, Gabriel FG, Johnson P, et al. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer 2010;103:656-62
   PubMed Web of Science ®Google Scholar
• Bianchini M, Levy E, Zucchini C, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006;29:83-94
   PubMed Web of Science ®Google Scholar
• Callari M, Dugo M, Musella V, et al. Comparison of microarray platforms for measuring differential microrna expression in paired normal/cancer colon tissues. PLoS ONE 2012;7:e45105
   PubMed Web of Science ®Google Scholar
• Erickson HS, Gillespie JW, Emmert-Buck MR. Tissue microdissection. Meth Mol Biol 2008;424:433-48
   PubMedGoogle Scholar
• Schmitt MW, Prindle MJ, Loeb LA. Implications of genetic heterogeneity in cancer. Ann NY Acad Sci 2012;1267:110-16
   PubMed Web of Science ®Google Scholar
• Tomaszewski JJ, Uzzo RG, Smaldone MC. Heterogeneity and renal mass biopsy: A review of its role and reliability. Cancer Biol Med 2014;11:162-72
   PubMedGoogle Scholar
• Bass BP, Engel KB, Greytak SR, et al. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med 2014;138:1520-30
   PubMed Web of Science ®Google Scholar
• Kashofer K, Viertler C, Pichler M, et al. Quality control of rna preservation and extraction from paraffin-embedded tissue: implications for RT-PCR and microarray analysis. PLoS One 2013;8:e70714
   PubMedGoogle Scholar
• Kissel HD, Paulson TG, Liu K, et al. Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays. Obst Gynecol Int 2013;2013:576842
   PubMedGoogle Scholar
• Weng L, Wu X, Gao H, et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010;222:41-51
   PubMed Web of Science ®Google Scholar
• Sinicropi D, Qu K, Collin F, et al. Whole transcriptome RNA-seq analysis of breast cancer recurrence risk using formalin-fixed paraffin-embedded tumor tissue. PLoS ONE 2012;7:e40092
   Google Scholar
• Schweiger MR, Kerick M, Timmermann B, et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One 2009;4:e5548
   PubMedGoogle Scholar
• Spencer DH, Sehn JK, Abel HJ, et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 2013;15:623-33
   PubMed Web of Science ®Google Scholar
• Tuononen K, Maki-Nevala S, Sarhadi VK, et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 2013;52:503-11
   PubMed Web of Science ®Google Scholar
• Hedegaard J, Thorsen K, Lund MK, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One 2014;9:e98187
   PubMed Web of Science ®Google Scholar
• Wheeler HE, Maitland ML, Dolan ME, et al. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 2013;14:23-34
   PubMed Web of Science ®Google Scholar
• Heidary M, Auer M, Ulz P, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014;16:421
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112-23
   PubMed Web of Science ®Google Scholar
• Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 2014;134:1207-13
   PubMed Web of Science ®Google Scholar
• Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012;18:2391-401
   PubMed Web of Science ®Google Scholar
• Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 2015;136:2158-65
   PubMed Web of Science ®Google Scholar
• Rothe F, Laes JF, Lambrechts D, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014;25:1959-65
   PubMed Web of Science ®Google Scholar
• Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One 2014;9:e103883
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014;345:216-20
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response. Expert Rev Mol Diagn 2015;15:267-75
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12
   PubMed Web of Science ®Google Scholar
• Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014;10:e1004271
   PubMed Web of Science ®Google Scholar
• Kim N, He N, Yoon S. Cell line modeling for systems medicine in cancers (review). Int J Oncol 2014;44:371-6
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5
   PubMed Web of Science ®Google Scholar
• Haibe-Kains B, El-Hachem N, Birkbak NJ, et al. Inconsistency in large pharmacogenomic studies. Nature 2013;504:389-93
   PubMed Web of Science ®Google Scholar
• Heiser LM, Sadanandam A, Kuo WL, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012;109:2724-9
   PubMed Web of Science ®Google Scholar
• Schafer CM, Campbell NG, Cai G, et al. Whole exome sequencing reveals minimal differences between cell line and whole blood derived DNA. Genomics 2013;102:270-7
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Lorenzi PL. Cancer: discrepancies in drug sensitivity. Nature 2013;504:381-3
   PubMed Web of Science ®Google Scholar
• Abaan OD, Polley EC, Davis SR, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 2013;73:4372-82
   PubMed Web of Science ®Google Scholar
• Ding J, Bashashati A, Roth A, et al. Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 2012;28:167-75
   PubMed Web of Science ®Google Scholar
• Liu B, Morrison CD, Johnson CS, et al. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget 2013;4:1868-81
   PubMedGoogle Scholar
• D’Antonio M, D’Onorio De Meo P, Paoletti D, et al. WEP: a high-performance analysis pipeline for whole-exome data. BMC Bioinformatics 2013;14(Suppl 7):S11
   PubMedGoogle Scholar
• Azam S, Rathore A, Shah TM, et al. An integrated SNP mining and utilization (ISMU) pipeline for next generation sequencing data. PLoS One 2014;9:e101754
   PubMedGoogle Scholar
• Xia J, Wang Q, Jia P, et al. NGS catalog: a database of next generation sequencing studies in humans. Hum Mutat 2012;33:E2341-55
   PubMed Web of Science ®Google Scholar
• Nasser S, Kurdolgu AA, Izatt T, et al. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. Pac Symp Biocomput 2015; 56-67
   Google Scholar
• Berg EL. Systems biology in drug discovery and development. Drug Discov Today 2014;19:113-25
   PubMed Web of Science ®Google Scholar
• Lin LL, Huang HC, Juan HF, et al. Deciphering molecular determinants of chemotherapy in gastrointestinal malignancy using systems biology approaches. Drug Discov Today 2014;19:1402-9
   PubMed Web of Science ®Google Scholar
• Allen WL, Stevenson L, Coyle VM, et al. A systems biology approach identifies sart1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther 2012;11:119-31
   PubMed Web of Science ®Google Scholar
• Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol 2014;11:109-18
   PubMed Web of Science ®Google Scholar
• McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905
   PubMed Web of Science ®Google Scholar
• Chen JJ LT-P, Chen D-T, Wang S-J. Biomarker adaptive designs in clinical trials. Transl Cancer Res 2014;3:279-92
   Google Scholar
• Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009;19:530-42
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34
   PubMed Web of Science ®Google Scholar
• Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60
   PubMed Web of Science ®Google Scholar
• Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Kopetz S, Tabernero J, Rosenberg R, et al. Genomic classifier coloprint predicts recurrence in stage ii colorectal cancer patients more accurately than clinical factors. Oncologist 2015;20:127-33
   PubMed Web of Science ®Google Scholar
• Simonds NI, Khoury MJ, Schully SD, et al. Comparative effectiveness research in cancer genomics and precision medicine: Current landscape and future prospects. J Natl Cancer Inst 2013;105:929-36
   PubMed Web of Science ®Google Scholar